Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks how leukemia drug works outside the lab

NCT ID NCT06092879

Ongoing Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 201 adults with chronic myeloid leukemia who are taking asciminib (Scemblix) as a third or later treatment option. Researchers want to see how long patients stay on the drug and how well it controls their cancer in real-world settings. The goal is to gather practical information that goes beyond clinical trials.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

asciminib (Scemblix)

What this could lead to

If successful, this study could provide real-world evidence on how well asciminib works and is tolerated in everyday practice for patients with chronic myeloid leukemia who have tried other treatments.

What could go wrong

This is an observational study, not a controlled trial, so results may be influenced by patient selection and real-world variability. It does not test a new treatment but gathers data on existing use.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic myelogenous leukemia, BCR-ABL1 positive Leukemia, Myelogenous, Chronic, BCR-ABL Positive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC MYELOID LEUKEMIA

Contacts and locations

Locations

  • Novartis Investigative Site

    Angers, France, 49933, France

  • Novartis Investigative Site

    Limoges, Haute Vienne, 87000, France

  • Novartis Investigative Site

    Saint Priest Jarez, Pays de la Loire Region, 42270, France

  • Novartis Investigative Site

    Aix-en-Provence, 13616, France

  • Novartis Investigative Site

    Amiens, 80054, France

  • Novartis Investigative Site

    Antibes, 06600, France

  • Novartis Investigative Site

    Avignon, 84000, France

  • Novartis Investigative Site

    Besançon, 25030, France

  • Novartis Investigative Site

    Bobigny, 93009, France

  • Novartis Investigative Site

    Bordeaux, 33000, France

  • Novartis Investigative Site

    Bordeaux, 33076, France

  • Novartis Investigative Site

    Brest, 29609, France

  • Novartis Investigative Site

    Brive-la-Gaillarde, 19100, France

  • Novartis Investigative Site

    Caen, 14033, France

  • Novartis Investigative Site

    Cagnes-sur-Mer, 06800, France

  • Novartis Investigative Site

    Cannes, 06414, France

  • Novartis Investigative Site

    Castelnau-le-Lez, 34170, France

  • Novartis Investigative Site

    Cesson-Sévigné, 35576, France

  • Novartis Investigative Site

    Chambéry, 73000, France

  • Novartis Investigative Site

    Clermont-Ferrand, 63003, France

  • Novartis Investigative Site

    Corbeil-Essonnes, 91100, France

  • Novartis Investigative Site

    Dunkirk, 59240, France

  • Novartis Investigative Site

    Essey-lès-Nancy, 54270, France

  • Novartis Investigative Site

    Grenoble, 38043, France

  • Novartis Investigative Site

    Le Kremlin-Bicêtre, 94275, France

  • Novartis Investigative Site

    Le Mans, 72000, France

  • Novartis Investigative Site

    Lens, 62307, France

  • Novartis Investigative Site

    Libourne, 33505, France

  • Novartis Investigative Site

    Lorient, 56100, France

  • Novartis Investigative Site

    Lyon, 69373, France

  • Novartis Investigative Site

    Montpellier, 34070, France

  • Novartis Investigative Site

    Montpellier, 34295, France

  • Novartis Investigative Site

    Mulhouse, 68070, France

  • Novartis Investigative Site

    Nantes, 44277, France

  • Novartis Investigative Site

    Nevers, 58000, France

  • Novartis Investigative Site

    Nîmes, 30029, France

  • Novartis Investigative Site

    Paris, 75013, France

  • Novartis Investigative Site

    Paris, 75015, France

  • Novartis Investigative Site

    Paris, 75475, France

  • Novartis Investigative Site

    Perpignan, 66046, France

  • Novartis Investigative Site

    Pierre-Bénite, 69495, France

  • Novartis Investigative Site

    Poitiers, 86021, France

  • Novartis Investigative Site

    Quimper, 29000, France

  • Novartis Investigative Site

    Rennes, 35033, France

  • Novartis Investigative Site

    Roubaix, 59100, France

  • Novartis Investigative Site

    Strasbourg, 67085, France

  • Novartis Investigative Site

    Tarbes, 65100, France

  • Novartis Investigative Site

    Toulouse, 31059, France

  • Novartis Investigative Site

    Tours, 37044, France

  • Novartis Investigative Site

    Valence, 26953, France

  • Novartis Investigative Site

    Vandœuvre-lès-Nancy, 54511, France

  • Novartis Investigative Site

    Vesoul, 70014, France